Phase III study of investigational C. diff vaccine begins in Canada
TORONTO | Sanofi Pasteur has announced the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection.